CN105381175A - Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases - Google Patents
Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases Download PDFInfo
- Publication number
- CN105381175A CN105381175A CN201510913406.3A CN201510913406A CN105381175A CN 105381175 A CN105381175 A CN 105381175A CN 201510913406 A CN201510913406 A CN 201510913406A CN 105381175 A CN105381175 A CN 105381175A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- coronary artery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 22
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 18
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000005202 decontamination Methods 0.000 claims description 3
- 230000003588 decontaminative effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims 5
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 244000194101 Ginkgo biloba Species 0.000 abstract description 13
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 8
- 210000004072 lung Anatomy 0.000 abstract description 8
- 230000036407 pain Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 241000399256 Pteromyini Species 0.000 abstract description 3
- 240000004980 Rheum officinale Species 0.000 abstract description 3
- 235000008081 Rheum officinale Nutrition 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 241000304531 Allium macrostemon Species 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract description 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241000735527 Eupatorium Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 240000005779 Jasminum multiflorum Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000222355 Trametes versicolor Species 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 239000006187 pill Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 230000001732 thrombotic effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 239000008899 fufang danshen Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 244000295724 Allium chinense Species 0.000 description 1
- 235000016790 Allium chinense Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 241000729196 Lycopus lucidus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000983344 Trachelospermum jasminoides Species 0.000 description 1
- 241000222354 Trametes Species 0.000 description 1
- 241000301399 Trogopterus xanthipes Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a traditional Chinese medicine composition in the preparation of drugs for treating coronary artery diseases, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine composition is made of the following raw materials: ginkgo leaf, Japanese eupatorium, coriolus versicolor, Chinese starjasmine stem, rheum officinale, flying squirrel feces, longstamen onion bulb, saposhnicovia divaricata, wolfberry, and licorice. The traditional Chinese medicine composition has the functions of activating blood circulation to dissipate blood stasis, freeing the channels, relieving pain, removing stasis, dissipating binds, moving qi, removing stagnation, tonifying the spleen, and boosting the lung, can treat both the symptoms and roots, has the advantages of rapid effect, strong pertinence, and no side or toxic effect, and can be used to prepare drugs for treating coronary artery diseases.
Description
Technical field
The invention belongs to tcm field, relate to
the purposes of Chinese medicine composition in preparation treatment coronary artery disease medicine.
Background technology
Coronary artery disease is called coronary heart disease, refers to because of coronary stricture, blood supply insufficiency and the myocardial dysfunction caused and (or) organic disease, therefore also known as ischemic cardiomyopathy.Typical symptom is exertional angina pectoris, occurs pareordia squeezing property pain when movable or excited, and shoulder is or/and upper left arm diffuses some patients left, and general lasting 5-10 minute, the medicines such as rest or buccal nitroglycerin can be alleviated.Part with uncomfortable in chest or based on uncomfortable in chest, severe patient pain is heavier, duration extension, have a rest or sleep time also can show effect.
For the treatment of coronary heart disease, there are western medical treatment method and Chinese traditional treatment method, western medical treatment method is mainly based on the medicine of expansion artery, and as nitroglycerin, amyl nitrite, arteries and veins heart Shu Tong etc., novel drugs also constantly updates appearance, but these Western medicine have its common limitation, i.e. effective a period of time during medication, drug withdrawal disease recurs again very soon, causes a lot of patients with coronary heart disease to become dependence to some Western medicine, often will standby in it, in case outbreak.Operative treatment also belongs to the category of doctor trained in Western medicine, successful operation can be removed and be gathered fat in certain section of blocked coronary arteries, patient's a period of time out of danger can be made, but the IC fat generation hidden danger of whole piece can not be removed, the safety of operative treatment is worrying, is not generally that dangerous patient does not perform a surgical operation.
Obtain extensive accreditation as the Chinese patent medicine in motherland's traditional medicine improving the curative effect centuries in coronary heart disease clinical symptoms etc., there is the not interchangeable advantage of other method.Chinese patent drugs for treatment is started with from integrally-regulated, acts on multiple pathology links of coronary heart disease, can symptomatic treatment in acute condition, relieving the primary symptom in a chronic case.For Heart pill of Musk, during first aid, sublingual administration can alleviate angina pectoris symptom rapidly, and long-term taking can increase functional or structural CC circulation, and this is just applicable to some patients not being fit to do bypass surgery mutually or participating in treatment very much.Even if some patients has implemented to put up a bridge or participate in treatment, but there is vascular restenosis after the treatment or inaccessible again time, Chinese patent medicine still can chronic administration, and also can obtain certain curative effect.And facility used by Chinese patent medicine, add the property complied of patient, curative effect is ensured, and the patent medicine of some classics, as Heart pill of Musk, the cheap financial burden that also can alleviate patient for the treatment of expenditure.
Chinese patent application 200910013275.8 discloses a kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease, by Rhizoma Acori Graminei, Radix Salviae Miltiorrhizae, Semen Platycladi, Radix Polygalae, Radix Ophiopogonis, Poria cum Radix Pini, Pollen Typhae, Carapax Et Plastrum Testudinis, Os Draconis, Herba Portulacae, the Radix Rehmanniae, Cornu Cervi, thorn five, Rhizoma Chuanxiong, Rhizoma Coptidis, Cortex Phellodendri, the Rhizoma Pinelliae, Rhizoma Corydalis, Rhizoma Curcumae Longae, Radix Angelicae Sinensis, the Radix Astragali, Semen Ziziphi Spinosae, Radix Achyranthis Bidentatae, the Radix Paeoniae Alba, Pheretima, Radix Ginseng, Radix Dipsaci, Folium Mori, Rhizoma Polygonati, Radix Rehmanniae Preparata, Rhizoma Curcumae, Semen Cassiae, Caulis Polygoni Multiflori, Herba Leonuri, Herba Epimedii, Rhizoma Drynariae, Radix Bupleuri, the Radix Aucklandiae, Rhizoma Atractylodis, Rhizoma Atractylodis Macrocephalae preparata, Fructus Aurantii, Rhizoma Polygoni Cuspidati, Pericarpium Citri Reticulatae, Herba Agrimoniae, Folium Perillae, Herba Artemisiae Scopariae, it is formulated that Margarita presses certain weight ratio, this pharmaceutical treatment coronary artery disease curative effect is fast, cure rate is high, but medicament Chinese crude drug broad categories, wherein containing Carapax Et Plastrum Testudinis, the medical materials such as Cornu Cervi, be unfavorable for protecting rare animal.
Summary of the invention
For solving the deficiencies in the prior art, the object of this invention is to provide
the purposes of Chinese medicine composition in preparation treatment coronary artery disease medicine.
For realizing object of the present invention, the present inventor, according to the research of theory of Chinese medical science and clinical test repeatedly and checking, provides one
the purposes of Chinese medicine composition in preparation treatment coronary artery disease medicine, described Chinese medicine composition is prepared from by the raw material of following parts by weight: Folium Ginkgo 10-25 part, Herba Lycopi 9-20 part, Coriolous Dersicolor (Fr.) Quel 9-15 part, Caulis Trachelospermi 9-15 part, Radix Et Rhizoma Rhei 9-15 part, Oletum Trogopterori 9-15 part, Bulbus Allii Macrostemonis 6-12 part, Radix Saposhnikoviae 6-12 part, Fructus Lycii 3-10 part and Radix Glycyrrhizae 2-12 part.
Preferably, described Chinese medicine composition is made up of the raw material of following weight portion: Folium Ginkgo 10 parts, Herba Lycopi 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Trachelospermi 9 parts, Radix Et Rhizoma Rhei 9 parts, Oletum Trogopterori 9 parts, Bulbus Allii Macrostemonis 6 parts, Radix Saposhnikoviae 6 parts, Fructus Lycii 3 parts and 2 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 18 parts, Herba Lycopi 15 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Trachelospermi 12 parts, Radix Et Rhizoma Rhei 12 parts, Oletum Trogopterori 12 parts, Bulbus Allii Macrostemonis 8 parts, Radix Saposhnikoviae 8 parts, Fructus Lycii 6 parts and 6 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 25 parts, Herba Lycopi 20 parts, Coriolous Dersicolor (Fr.) Quel 15 parts, Caulis Trachelospermi 15 parts, Radix Et Rhizoma Rhei 15 parts, Oletum Trogopterori 15 parts, Bulbus Allii Macrostemonis 12 parts, Radix Saposhnikoviae 12 parts, Fructus Lycii 10 parts and 12 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into granule, tablet, capsule, pill, oral liquid or powder.
Preferably, described Chinese medicine composition is obtained by following steps:
(1): take Folium Ginkgo, Herba Lycopi, Coriolous Dersicolor (Fr.) Quel, Caulis Trachelospermi, Radix Et Rhizoma Rhei, Oletum Trogopterori, Bulbus Allii Macrostemonis, Radix Saposhnikoviae, Fructus Lycii and Radix Glycyrrhizae, decontamination, mixing is ground into coarse powder, add the purified water of above-mentioned coarse powder total amount 6-12 times amount, soak 2-3 hour, intense fire decocts boiling 30-60 minute, then uses slow fire boiling 1-3 hour, filter and retain filtering residue, obtaining the first filtrate;
(2): the purified water adding described filtering residue total amount 2-6 times amount toward above-mentioned filtering residue, intense fire decocts boiling 25-40 minute, then uses slow fire boiling 1-3 hour, filters, obtains the second filtrate;
(3): merge described first filtrate and described second filtrate, it is the concentrated solution of 1.15-1.25 that filtrate is concentrated into relative density at 60 DEG C, for subsequent use;
(4): above-mentioned concentrated solution being concentrated into 60 DEG C of relative densities is the thick paste of 1.15-1.25, drying under reduced pressure, cross 100-200 mesh sieve after pulverizing, obtain uniform fine powder, to obtain final product.
Source, the nature and flavor of Chinese medicine composition of the present invention Chinese crude drug used, return through and effect:
Folium Ginkgo: this product is the dried leaves of Ginkgoaceae plant Ginkgo biloba; Property is put down; Sweet in the mouth, hardship, puckery; GUIXIN, lung meridian; Blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, astringes the lung and relievings asthma, and changes turbid blood fat reducing.
Herba Lycopi: this product is the dry aerial parts of labiate hair leaf lycopus lucidus; Bitter in the mouth, pungent, slightly warm in nature; Return liver, spleen channel; Blood circulation promoting and blood stasis dispelling, line water detumescence.
Coriolous Dersicolor (Fr.) Quel: this product is the dry sporophore of Polyporaceae Trametes; Sweet in the mouth, light; Cold nature; Return liver, spleen channel; Heat clearing away, removing toxic substances, antiinflammatory, anticancer, protect the liver.
Caulis Trachelospermi: this product is the dry zone leaf rattan of apocynaceae plant trachelospermum jasminoide; Bitter in the mouth, cold nature; GUIXIN, liver, kidney channel; Dispelling wind and removing obstruction in the collateral, removing heat from blood is subsided a swelling.
Radix Et Rhizoma Rhei: this product is the rhizome of polygonum rheum palmatum, Rheum tanguticum or Rheum officinale; Bitter in the mouth, cold in nature; Return spleen, stomach, large intestine, liver, pericardium channel; Purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.
Oletum Trogopterori: this product is flying squirrel section animal trogopterus xanthipes or the dry feces flying the little flying squirrel of murine; Sweet in the mouth, warm in nature; Return Liver Channel; Promoting blood circulation to remove blood stasis, parch to black stops blooding.
Bulbus Allii Macrostemonis: this product is the dry bulb of liliaceous plant Allium macrostemon or Chinese onion; Acrid in the mouth, hardship, warm in nature; Return lung, stomach, large intestine channel; Activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving.
Radix Saposhnikoviae: this product is the dry root of umbelliferae Saposhnikovia divaricata; Acrid in the mouth, sweet, warm in nature; Return bladder, liver, spleen channel; Inducing diaphoresis to dispel wind, victory is wet, relieving convulsion.
Fructus Lycii: this product is the mature fruit of matrimony vine of solanaceae plant; Sweet in the mouth; Property is put down; Return liver, kidney channel; Nourishing the liver and kidney, replenishing vital essence to improve eyesight.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; Gui Jing, GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The prescription analysis of Chinese medicine of the present invention:
According to the compatibility theory of the traditional Chinese medical science to the dialectical of coronary artery disease and Chinese crude drug, in conjunction with the body constitution of modern and the feature of modern pharmaceutical technology, the collocation ingredients of reasonable science, forms Chinese prescription of the present invention.Prescription of the present invention is with Folium Ginkgo, Herba Lycopi for monarch drug, blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, clearing away heat and cooling blood; With Coriolous Dersicolor (Fr.) Quel, Caulis Trachelospermi and Radix Et Rhizoma Rhei for ministerial drug, removing heat from blood promotes the production of body fluid, dispelling wind and removing obstruction in the collateral, removing pathogenic heat from blood and toxic substance from the body; With Oletum Trogopterori, Bulbus Allii Macrostemonis, Radix Saposhnikoviae for adjuvant drug, eliminating blood stasis and inducing menstruation, activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving; With Fructus Lycii and Radix Glycyrrhizae for making medicine, nourishing the liver and kidney, heat clearing and damp drying, invigorating the spleen to benefit the lung, heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription; The all medicines of monarch coordinate, and collaborative promotion, complements each other, finally reach blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, eliminating stasis and resolving masses, circulation of qi promoting intestinal stasis relieving, effect of invigorating the spleen to benefit the lung.
Chinese medicine composition of the present invention comes from the achievement in research of China's Chinese medical theory and modern pharmacology, through pharmacodynamic experiment research, clinical practice treatment use, proves its determined curative effect in treatment coronary artery disease.Chinese medicine composition of the present invention has blood circulation promoting and blood stasis dispelling, removing obstruction in the collateral to relieve pain, eliminating stasis and resolving masses, circulation of qi promoting intestinal stasis relieving, effect of invigorating the spleen to benefit the lung, and its instant effect is with strong points, and do not recur, medication is simple and convenient, without any side effects.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, be all included within the scope of the present invention.
eXAMPLE l
This Chinese medicine composition pill is made up of the raw material of following parts by weight: Folium Ginkgo 10 parts, Herba Lycopi 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Trachelospermi 9 parts, Radix Et Rhizoma Rhei 9 parts, Oletum Trogopterori 9 parts, Bulbus Allii Macrostemonis 6 parts, Radix Saposhnikoviae 6 parts, Fructus Lycii 3 parts and 2 parts, Radix Glycyrrhizae.
Preparation method:
(1): take Folium Ginkgo, Herba Lycopi, Coriolous Dersicolor (Fr.) Quel, Caulis Trachelospermi, Radix Et Rhizoma Rhei, Oletum Trogopterori, Bulbus Allii Macrostemonis, Radix Saposhnikoviae, Fructus Lycii and Radix Glycyrrhizae, decontamination, mixing is ground into coarse powder, add the purified water of above-mentioned coarse powder total amount 8 times amount, soak 2 hours, intense fire decocts boiling 40 minutes, then uses slow fire boiling 2 hours, filter and retain filtering residue, obtaining the first filtrate;
(2): the purified water adding described filtering residue total amount 4 times amount toward above-mentioned filtering residue, intense fire decocts boiling 30 minutes, then uses slow fire boiling 2 hours, filters, obtains the second filtrate;
(3): merge described first filtrate and described second filtrate, it is the concentrated solution of 1.20 that filtrate is concentrated into relative density at 60 DEG C, for subsequent use;
(4): above-mentioned concentrated solution being concentrated into 60 DEG C of relative densities is the thick paste of 1.20, drying under reduced pressure, cross 150 mesh sieves after pulverizing, obtain uniform fine powder, add corresponding adjuvant and make pill.
embodiment 2
This Chinese medicine composition pill is made up of the raw material of following parts by weight: Folium Ginkgo 18 parts, Herba Lycopi 15 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Trachelospermi 12 parts, Radix Et Rhizoma Rhei 12 parts, Oletum Trogopterori 12 parts, Bulbus Allii Macrostemonis 8 parts, Radix Saposhnikoviae 8 parts, Fructus Lycii 6 parts and 6 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3
This Chinese medicine composition pill is made up of the raw material of following parts by weight: Folium Ginkgo 25 parts, Herba Lycopi 20 parts, Coriolous Dersicolor (Fr.) Quel 15 parts, Caulis Trachelospermi 15 parts, Radix Et Rhizoma Rhei 15 parts, Oletum Trogopterori 15 parts, Bulbus Allii Macrostemonis 12 parts, Radix Saposhnikoviae 12 parts, Fructus Lycii 10 parts and 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
test example 1 Chinese medicine composition of the present invention is tested the impact of rat experiment myocardial inyaretion
1.1 test method
1.1.1, experimental animal and grouping:
Experimental animal gets healthy cleaning grade Kunming kind rat 110, be divided into 11 groups, often organize 10, male and female half and half, model group, test medicine A group (high, medium and low dosage group), test medicine B group (high, medium and low dosage group), test medicine C group (high, medium and low dosage group), positive controls (FUFANG DANSHEN PIAN is divided at random by body weight, Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, the accurate word of traditional Chinese medicines: Z11021185).
1.1.2, trial drug and dosage regimen:
Each dosage group equal-volume not isoconcentration gastric infusion 7 days, once a day, wherein:
A group: trial drug is the pill that the embodiment of the present invention 1 obtains.Get 3 groups of mices, be labeled as A group high dose group (0.8g/kg), middle dosage group (0.4g/kg) and low dose group (0.2g/kg) respectively, in last administration after 1 hour, rat is fixed with etherization, under artificial respirator, quick opening operation breast, exposes heart, by the ligation of anterior descending coronary root.Block coronary blood flow, rapidly heart is put back to abdominal cavity, sew up thoracic wall.After 24 hours, put to death rat, core dirty, clean remaining blood, removing atrium and blood vessel, thinly slice after ventricle is weighed, be positioned in 0.5% nitro blue tetrazolium solution, hatch 15 minutes for 37 DEG C, cut off painted cardiac muscle (myocardial infarction is not painted), infarcted myocardium is weighed, is calculated as follows infarct size:
Infarct size=myocardial infarction area/myocardial Mass Measured X100%
B group: trial drug is the pill that the embodiment of the present invention 2 obtains, and dosage regimen is with A group.
C group: trial drug is the pill that the embodiment of the present invention 3 obtains, and dosage regimen is with A group.
Positive controls: positive control drug is FUFANG DANSHEN PIAN, (Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, the accurate word of traditional Chinese medicines: Z11021185), positive drug group mice gives 0.8g/kg (10 times for the clinical consumption per day of adult) every day.
Model group: fill with and equal-volume distilled water, gavage volume 0.1ml10g-
1.
1.2, experimental result:
as table 1shown in.
table 1medicine is on the impact of rat experiment myocardial inyaretion
Note: compare with model control group,
* p< 0.05,
* p< 0.01; Compare with positive controls,
# p< 0.05,
## p< 0.05.
By
table 1visible, compared with model group, A group of the present invention, B group, C group and positive controls all can make Rat Experimental myocardial infarction area significantly reduce, statistical discrepancy significantly (
p< 0.05), Chinese medicine composition of the present invention, compared with positive controls, has significant difference, therefore can think, the Chinese medicine composition pill that the present invention obtains, and in tested dosage range, has the impact reducing myocardial infarction.
test example 2, Chinese medicine composition of the present invention are on the thrombotic impact experiment of rat vein
2.1 test method
2.1.1, experimental animal and grouping:
Get male rat 110, model control group, test medicine A group (3 dosage groups), test medicine B group (3 dosage groups), test medicine C group (3 dosage groups), positive controls (FUFANG DANSHEN PIAN is divided at random by body weight, Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory, the accurate word of traditional Chinese medicines: Z11021185).
2.1.2, trial drug and dosage regimen:
Every day gastric infusion or contrast liquid (normal saline) once, successive administration 7 days, period free diet.Wherein, model control group, test medicine group and positive controls respectively organize the same 1.1.2 of drug test scheme.
Last administration is after 30 minutes, use the fixing rat of 0.5% urethane anesthesia, be separated left (right side) side common carotid artery and right (left side) jugular vein, get stage casing and have 5cm silk thread and the polyethylene tube being full of heparin sodium aqua (50u/ml), carry out arteriovenous bridging, open blood flow is middle Herba Clinopodii after 15 minutes, and take fine rule, gross weight cuts off fine rule weight and is wet weight of thrombus.
2.2, experimental result:
as table 2shown in.
table 2medicine is on the thrombotic impact of rat vein
Note: compare with model group,
* p< 0.05,
* p< 0.01; Compared with matched group,
# p< 0.05,
## p< 0.05.
By
table 2visible, A group of the present invention, B group, C group and positive controls rat vein thrombosis weight in wet base and model control group more all have significant difference (
p< 0.05), therefore can to think, after the treatment of Chinese medicine composition of the present invention and positive controls FUFANG DANSHEN PIAN medicine, all significantly to reduce than the wet weight of thrombus of model group rats.Chinese medicine composition of the present invention and positive Compositae Salviae Miltiorrhizae medicine all effectively have the thrombotic effect of suppression rat vein as can be seen here, Chinese medicine composition of the present invention has the thrombotic effect trend of suppression rat vein in tested dosage range, wherein especially best with the Chinese medicine composition effect of the present invention that the embodiment of the present invention 2 is obtained, therefore embodiment 2 is preferred embodiment.
3 conclusion (of pressure testing)s.
Test data shows, and Chinese medicine composition of the present invention, in tested dosage range, has the impact reducing myocardial infarction, effectively can suppress the thrombotic effect trend of rat vein.The basic, normal, high dosage group of A group in this experiment, B group basic, normal, high dosage group and C group basic, normal, high dosage group experiment effect obvious, the wherein high dose group best results of B group (the Chinese medicine composition pill of the present invention that namely embodiment of the present invention 2 is obtained), have significantly reduce myocardial infarction impact (
p< 0.05), can effectively suppress the thrombotic effect trend of rat vein (
p< 0.01), illustrate that test medicine has the function for the treatment of coronary artery disease.
In addition, the pill that embodiment of the present invention 1-3 is prepared by inventor carries out clinical trial to 180 volunteers, evident in efficacy, and has no side effect, and illustrates that Chinese medicine composition of the present invention can be used as the medicinal application of preparation treatment coronary artery disease in clinical treatment.
Claims (5)
1. the purposes of Chinese medicine composition in preparation treatment coronary artery disease medicine, it is characterized in that, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 10-25 part, Herba Lycopi 9-20 part, Coriolous Dersicolor (Fr.) Quel 9-15 part, Caulis Trachelospermi 9-15 part, Radix Et Rhizoma Rhei 9-15 part, Oletum Trogopterori 9-15 part, Bulbus Allii Macrostemonis 6-12 part, Radix Saposhnikoviae 6-12 part, Fructus Lycii 3-10 part and Radix Glycyrrhizae 2-12 part.
2. the purposes of Chinese medicine composition as claimed in claim 1 in preparation treatment coronary artery disease medicine, it is characterized in that, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 10 parts, Herba Lycopi 9 parts, Coriolous Dersicolor (Fr.) Quel 9 parts, Caulis Trachelospermi 9 parts, Radix Et Rhizoma Rhei 9 parts, Oletum Trogopterori 9 parts, Bulbus Allii Macrostemonis 6 parts, Radix Saposhnikoviae 6 parts, Fructus Lycii 3 parts and 2 parts, Radix Glycyrrhizae.
3. the purposes of Chinese medicine composition as claimed in claim 1 in preparation treatment coronary artery disease medicine, it is characterized in that, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 18 parts, Herba Lycopi 15 parts, Coriolous Dersicolor (Fr.) Quel 12 parts, Caulis Trachelospermi 12 parts, Radix Et Rhizoma Rhei 12 parts, Oletum Trogopterori 12 parts, Bulbus Allii Macrostemonis 8 parts, Radix Saposhnikoviae 8 parts, Fructus Lycii 6 parts and 6 parts, Radix Glycyrrhizae.
4. the purposes of Chinese medicine composition as claimed in claim 1 in preparation treatment coronary artery disease medicine, it is characterized in that, described Chinese medicine composition is made up of the raw material of following parts by weight: Folium Ginkgo 25 parts, Herba Lycopi 20 parts, Coriolous Dersicolor (Fr.) Quel 15 parts, Caulis Trachelospermi 15 parts, Radix Et Rhizoma Rhei 15 parts, Oletum Trogopterori 15 parts, Bulbus Allii Macrostemonis 12 parts, Radix Saposhnikoviae 12 parts, Fructus Lycii 10 parts and 12 parts, Radix Glycyrrhizae.
5. the purposes of the Chinese medicine composition as described in any one of claim 1-4 in preparation treatment coronary artery disease medicine, it is characterized in that, described Chinese medicine composition is obtained by following steps:
(1): take Folium Ginkgo, Herba Lycopi, Coriolous Dersicolor (Fr.) Quel, Caulis Trachelospermi, Radix Et Rhizoma Rhei, Oletum Trogopterori, Bulbus Allii Macrostemonis, Radix Saposhnikoviae, Fructus Lycii and Radix Glycyrrhizae, decontamination, mixing is ground into coarse powder, add the purified water of above-mentioned coarse powder total amount 6-12 times amount, soak 2-3 hour, intense fire decocts boiling 30-60 minute, then uses slow fire boiling 1-3 hour, filter and retain filtering residue, obtaining the first filtrate;
(2): the purified water adding described filtering residue total amount 2-6 times amount toward above-mentioned filtering residue, intense fire decocts boiling 25-40 minute, then uses slow fire boiling 1-3 hour, filters, obtains the second filtrate;
(3): merge described first filtrate and described second filtrate, it is the concentrated solution of 1.15-1.25 that filtrate is concentrated into relative density at 60 DEG C, for subsequent use;
(4): above-mentioned concentrated solution being concentrated into 60 DEG C of relative densities is the thick paste of 1.15-1.25, drying under reduced pressure, cross 100-200 mesh sieve after pulverizing, obtain uniform fine powder, obtain this Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913406.3A CN105381175A (en) | 2015-12-12 | 2015-12-12 | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510913406.3A CN105381175A (en) | 2015-12-12 | 2015-12-12 | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105381175A true CN105381175A (en) | 2016-03-09 |
Family
ID=55414351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510913406.3A Withdrawn CN105381175A (en) | 2015-12-12 | 2015-12-12 | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105381175A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663614A (en) * | 2016-03-29 | 2016-06-15 | 广州三得医疗科技有限公司 | Pharmaceutical composition containing folium artemisiae argyi and capable of promoting blood circulation to remove blood stasis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283471A (en) * | 2000-07-04 | 2001-02-14 | 王汝明 | Tea for nursing cardiac and cerebral blood vessel |
| CN103316302A (en) * | 2013-07-08 | 2013-09-25 | 陈静静 | Chinese medicine formula for treating angina pectoris |
| KR20140066846A (en) * | 2012-11-22 | 2014-06-02 | 한국식품연구원 | Composition for preventing, treating or improving of metabolic disease comprising morus alba leaf and cudrania tricuspidata leaf as an active ingredient |
-
2015
- 2015-12-12 CN CN201510913406.3A patent/CN105381175A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283471A (en) * | 2000-07-04 | 2001-02-14 | 王汝明 | Tea for nursing cardiac and cerebral blood vessel |
| KR20140066846A (en) * | 2012-11-22 | 2014-06-02 | 한국식품연구원 | Composition for preventing, treating or improving of metabolic disease comprising morus alba leaf and cudrania tricuspidata leaf as an active ingredient |
| CN103316302A (en) * | 2013-07-08 | 2013-09-25 | 陈静静 | Chinese medicine formula for treating angina pectoris |
Non-Patent Citations (1)
| Title |
|---|
| 姚金玲等: "《职工健康指南》", 31 January 2013, 中国商业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663614A (en) * | 2016-03-29 | 2016-06-15 | 广州三得医疗科技有限公司 | Pharmaceutical composition containing folium artemisiae argyi and capable of promoting blood circulation to remove blood stasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057946B (en) | Traditional Chinese medicine for treating heart disease | |
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN104383115A (en) | Traditional Chinese medicine preparation for treating coronary heart disease and preparation method of traditional Chinese medicine preparation | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN102512632B (en) | Chinese herbal composition for treating abnormal menstruation | |
| CN104258350A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome and preparation method of traditional Chinese medicine preparation | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN105797081A (en) | Pharmaceutical composition for treating amenorrhea | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN104523873A (en) | Pharmaceutical composition for treating gout | |
| CN105381175A (en) | Application of traditional Chinese medicine composition in preparation of drugs for treating coronary artery diseases | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN105169338A (en) | Medicine composition for treating female climacteric syndromes and preparation method thereof | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN105412834A (en) | Application of traditional Chinese medicine composition in preparing medicine for treating CAD (Coronary Artery Disease) | |
| CN104645247B (en) | A kind of Chinese medicine preparation for treating hepatolenticular degeneration and preparation method thereof | |
| CN105497455A (en) | Application of traditional Chinese medicine preparation to preparing drug for treating coronary sclerosis | |
| CN105396064A (en) | A use of a traditional Chinese medicine preparation in preparation of medicines treating coronary atherosclerosis | |
| CN105456920A (en) | Application of traditional Chinese medicinal composition in preparing medicine for treating coronary artery disease | |
| CN105770815A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160309 |
|
| WW01 | Invention patent application withdrawn after publication |